FANUC Top 100 Global Innovators 2026 by Clarivate
For the fifth consecutive year, FANUC Corporation has been recognized by Clarivate Plc as one of the Top 100 Global Innovators for 2026, largely due to its significant advancements and patent filings in AI technology for industrial automation. The company is actively investing in AI research and development, particularly for numerical control devices and robot control, and aims to strengthen its intellectual property portfolio to support sustainable growth and address global challenges. This recognition highlights FANUC's commitment to leveraging technological innovation to solve social and environmental issues.
When healthcare payers grant market access to premium-priced, more convenient treatments
This article examines three case studies—HIV pre-exposure prophylaxis, hemophilia A prophylaxis, and opioid use disorder—to demonstrate how long-acting injectable (LAI) treatments achieve premium pricing and broad market access despite being more expensive than generic options. It attributes this phenomenon to limited payer leverage and policy-driven coverage mandates in these specific therapeutic areas, where "sweet spots" for market access exist. The author emphasizes that these dynamics are not universally applicable and suggests value frameworks should better differentiate between adherence-driven benefits and policy-mandated coverage.
Clarivate stock hits 52-week low at $1.74
Clarivate PLC's stock recently hit a 52-week low of $1.74, reflecting a significant 63.77% decline over the past year. Despite current unprofitability and analyst downgrades from Goldman Sachs and Morgan Stanley, InvestingPro data suggests the stock might be undervalued with strong gross profit margins and oversold RSI indicators, forecasting a return to profitability this year. The company recently redeemed $100 million in senior secured notes, demonstrating efforts to manage financial obligations.
Clarivate (CLVT) Valuation Check After Debt Redemption, Share Buybacks And Nexus AI Assistant Launch
Clarivate (CLVT) has been under scrutiny after redeeming debt, increasing share repurchases, and launching its Nexus AI assistant, yet its stock has seen significant declines. Despite a current share price of $1.84, which is significantly below analyst targets and intrinsic value estimates of $4.61, the market appears cautious. The company's future valuation hinges on factors like AI-driven product innovation, competitive landscape, and managing its debt.
Clarivate stock hits 52-week low at $1.74
Clarivate PLC's stock has fallen to a 52-week low of $1.74, representing a 63.77% decline over the past year. Despite current unprofitability, analysts forecast a return to positive EPS this year, and InvestingPro data suggests the stock may be undervalued with strong gross profit margins and a low Price/Book ratio, while the RSI indicates it is oversold. The company recently redeemed $100 million in senior secured notes, but has faced downgrades from Goldman Sachs and Morgan Stanley due to concerns about its growth prospects and Value Creation Plan timeline.
The IRA could hurt market access for more convenient drugs
The Inflation Reduction Act (IRA) may unintentionally disincentivize Medicare plans from covering more convenient, self-administered subcutaneous (SC) therapies, favoring intravenous (IV) formulations instead. This is due to different out-of-pocket caps for patients—$2,000 for self-administered drugs and $9,350 for IV treatments under Medicare Advantage, or no cap for traditional Medicare IVs—which can make SC options more expensive for health plans. While SC versions offer patient convenience and equivalent efficacy, Medicare plans are showing a preference for IV access to control costs, unlike commercial plans which have smaller coverage gaps.
The RiskMark updates for 2026
Clarivate has announced significant updates to its RiskMark platform for 2026, integrating AI and industry advancements to provide a more comprehensive and nuanced approach to trademark analysis. The enhancements include visual comparison for device marks, multilingual drafting capabilities, and automatic identification of weak elements within marks. These new features aim to move RiskMark beyond a text-driven comparison engine to a holistic trademark evaluation platform.
Announcing the Clarivate Academic AI Working Group
Clarivate is launching the Academic AI Working Group to deepen collaboration with academic professionals and guide the development of AI tools in research and education. This group will provide practical, hands-on insights into product development, user experience, and responsible AI guardrails, complementing the strategic focus of the existing Academia AI Advisory Council. Clarivate is seeking diverse academic professionals to join the working group, offering them early visibility into new AI capabilities and a direct role in shaping future solutions.
Clarivate (CLVT) reveals new AI academic assistant, to launch in Q3 2026
Clarivate (CLVT) has announced the development of a new AI-powered academic assistant, designed to enhance research processes for scholars. The company plans to launch this innovative tool in the third quarter of 2026, aiming to leverage artificial intelligence to support academic endeavors.
How Debt Redemption And Buybacks Plus AI Launch At Clarivate (CLVT) Has Changed Its Investment Story
Clarivate Plc recently redeemed US$100 million in debt and repurchased 56 million shares, alongside launching Clarivate Nexus, an AI-powered academic assistant. These actions aim to simplify its balance sheet and embed AI into its information services, potentially strengthening its investment narrative and supporting its goal of stabilizing organic revenue and improving profitability by 2028. Investors should consider how AI adoption and customer concentration risks might impact future performance.
Clarivate (CLVT) Valuation Check As AI Webinar Puts Its Data And Tools Back In Focus
Clarivate (CLVT) is gaining attention due to an upcoming AI webinar focusing on new AI tools built on its proprietary data. Despite recent share price momentum, the stock is considered significantly undervalued at $2.17 compared to a narrative-based fair value of $4.68, driven by expectations of AI-powered product innovation. However, this valuation relies on sustained higher education funding and Clarivate maintaining its competitive edge.
Clarivate Plc (CLVT) Takes Steps to Reshape Financial Structure and Product Strategy
Clarivate Plc (CLVT) has taken steps to restructure its finances by redeeming $100 million in senior secured notes and repurchasing shares to simplify its capital structure and reduce debt. The company also introduced Clarivate Nexus, an AI-powered academic assistant, amidst a downgrade by Goldman Sachs due to concerns about its Value Creation Plan. These actions aim to improve financial flexibility and drive innovation, although Goldman Sachs believes it will take time to impact organic revenue growth.
Clarivate Plc (CLVT) Takes Steps to Reshape Financial Structure and Product Strategy
Clarivate Plc (CLVT) has taken steps to restructure its finances by redeeming $100 million of its senior secured notes and repurchasing shares to simplify its capital structure and reduce debt. The company also launched Clarivate Nexus, an AI-powered academic assistant, despite a recent downgrade from Goldman Sachs due to concerns about its Value Creation Plan. Clarivate aims to improve its organic revenue growth by transitioning to subscription offerings and enhancing product innovation.
Clarivate stock hits 52-week low at $1.99 By Investing.com
Clarivate PLC's stock recently reached a new 52-week low of $1.99, reflecting a significant 59.88% decline over the past year. Despite not being profitable in the last twelve months, the company shows impressive gross profit margins and a strong free cash flow yield. Analyst downgrades from Goldman Sachs and Morgan Stanley, citing concerns over slow revenue growth and limited operating leverage, contribute to a cautious outlook ahead of its earnings report.
Clarivate stock hits 52-week low at $1.99 By Investing.com
Clarivate Plc's stock has plunged to a new 52-week low of $1.99, marking a nearly 60% decline over the past year. Despite not being profitable in the last twelve months, the company boasts strong gross profit margins and free cash flow yield. The downturn follows recent analyst downgrades from Goldman Sachs and Morgan Stanley due to concerns over growth prospects and the timeline for its Value Creation Plan.
Clarivate’s Subsidiary Redeems The Remaining 2026 Senior Secured Notes
Clarivate Plc's subsidiary, Camelot Finance S.A., has redeemed the remaining $100 million of its 4.50% senior secured notes due 2026. This move, funded with cash on hand, is part of Clarivate's strategy to simplify its capital structure, minimize debt, and enhance financial flexibility. The company also repurchased approximately 56 million CLVT shares for $225 million in FY2025.
Clarivate's Subsidiary Redeems The Remaining 2026 Senior Secured Notes
Clarivate Plc's subsidiary, Camelot Finance S.A., has redeemed the remaining $100 million aggregate principal amount of its 4.50% senior secured notes due 2026, issued in October 2019. This move, completed on January 30, 2026, is part of Clarivate's strategy to simplify its capital structure, reduce debt, and enhance financial flexibility, funded by cash on hand. The company also reported significant share repurchases in FY2025, buying back 56 million CLVT shares for $225 million.
Clarivate’s subsidiary redeems the remaining 2026 senior secured notes
Clarivate's subsidiary has redeemed all of its outstanding 2026 Senior Secured Notes using cash on hand. This action fully repays the notes that were originally due on July 1, 2026. The move aims to optimize the company's capital structure.
Clarivate’s Subsidiary Redeems The Remaining 2026 Senior Secured Notes
Clarivate Plc's subsidiary, Camelot Finance S.A., has redeemed the remaining $100 million principal amount of its 4.50% senior secured notes due 2026. This move simplifies Clarivate's capital structure, reduces debt, and enhances financial flexibility. The company also repurchased approximately $225 million worth of CLVT shares in FY2025.
Clarivate Plc's (NYSE:CLVT) 35% Dip In Price Shows Sentiment Is Matching Revenues
Clarivate Plc (NYSE:CLVT) has experienced a 35% share price drop in the last month, contributing to a 59% decline over the past year. The company's low price-to-sales (P/S) ratio of 0.6x is attributed to its declining revenue and a projected future growth of only 0.2% annually, significantly lagging the professional services industry's forecast of 6.5%. This indicates that the market's negative sentiment reflects the company's underperformance relative to its peers.
Clarivate Webinar "Intelligence Amplified in the Age of AI" Highlights How Trusted, Proprietary Data Powers Next‑Generation Innovation
Clarivate Plc (NYSE: CLVT) has launched a webinar titled "Intelligence Amplified in the Age of AI," showcasing how the company utilizes artificial intelligence to enhance research and innovation across scientific, academic, intellectual property, and life sciences sectors. CEO Matti Shem Tov emphasized Clarivate's strong position due to its proprietary solutions and deep domain expertise, which are amplified by AI. The webinar demonstrates practical applications of AI through research assistants, workflow automation, and extended ecosystem access, all powered by Clarivate's trusted, curated data designed to minimize hallucination risks.
Clarivate Webinar "Intelligence Amplified in the Age of AI" Highlights How Trusted, Proprietary Data Powers Next‑Generation Innovation
Clarivate Plc launched a webinar titled "Intelligence Amplified in the Age of AI" featuring CEO Matti Shem Tov, exploring how the company leverages AI with its proprietary data to enhance research, innovation, and decision-making across various ecosystems. The session emphasizes Clarivate's unique position due to its expert-curated, AI-ready data, which underpins AI Research Assistants, AI Workflow Agents, and AI Ecosystem Access, ensuring accuracy and reliability in high-stakes environments. The company stresses that AI augments, rather than replaces, human expertise.
Clarivate (NYSE:CLVT) Reaches New 12-Month Low - Should You Sell?
Clarivate (NYSE:CLVT) has hit a new 52-week low of $2.59, trading well below its 50- and 200-day moving averages, signaling a strong downtrend. Analysts have significantly lowered their ratings and price targets for the stock, with a MarketBeat consensus of "Reduce" and a target price of $4.28. The company's fundamentals show weak liquidity and a negative P/E ratio, despite mixed insider and institutional ownership activity.
Clarivate redeems $100 million in senior secured notes By Investing.com
Clarivate Plc has fully redeemed $100 million of its 4.50% senior secured notes due 2026, using cash on hand. This move is part of the company's strategy to manage its substantial debt and simplify its capital structure. Additionally, Clarivate repurchased approximately 56 million shares for $225 million in 2025, suggesting potential undervaluation according to InvestingPro.
Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities – Company Announcement
Clarivate Plc announced the full redemption of the remaining $100 million of its 4.50% senior secured notes due 2026, funded with cash on hand, to simplify its capital structure and enhance financial flexibility. The company also reported repurchasing approximately 21 million ordinary shares for $75 million in Q4 2025, bringing the full year 2025 total to 56 million shares for $225 million, as part of its capital allocation strategy. These actions demonstrate Clarivate's commitment to strengthening its balance sheet and returning capital to shareholders.
What healthcare payers reward: adherence versus outcomes
This article examines how healthcare payers evaluate new drug therapies, distinguishing between therapies that offer improved adherence and those that deliver measurable clinical and economic outcomes. Through two case studies—NEULASTA Onpro and CABENUVA—it demonstrates that payers prioritize solutions that show immediate, quantifiable cost savings and better patient outcomes within their typical budget horizons (1-2 years), rather than simply convenience or the promise of better adherence alone. The core takeaway is that an "adherence premium" only translates into an "outcome premium" when data prove significant cost savings.
Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities
Clarivate Plc announced that its subsidiary, Camelot Finance S.A., has fully redeemed the remaining $100 million of its 4.50% senior secured notes due 2026 using cash on hand, simplifying its capital structure and reducing debt. Additionally, Clarivate repurchased approximately 21 million ordinary shares for $75 million in Q4 2025, contributing to a total of 56 million shares repurchased for $225 million throughout 2025 as part of its capital allocation strategy. These actions aim to strengthen the balance sheet, enhance financial flexibility, and drive long-term shareholder value.
Clarivate redeems $100 million in senior secured notes
Clarivate Plc (NYSE:CLVT) has fully redeemed the remaining $100 million of its 4.50% senior secured notes due 2026, using cash on hand. This move is part of the company's strategy to simplify its capital structure, reduce debt, and enhance financial flexibility, complemented by aggressive share repurchases totaling $225 million in 2025. The announcement comes amidst recent downgrades by Goldman Sachs and Morgan Stanley due to concerns about the company's organic revenue growth and operating leverage.
Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities – Company Announcement
Clarivate Plc announced its subsidiary, Camelot Finance S.A., fully redeemed the remaining $100 million of its 4.50% senior secured notes due 2026 on January 30, 2026, using cash on hand. This action is part of Clarivate's strategy to simplify its capital structure and reduce debt. The company also repurchased approximately 56 million ordinary shares for $225 million throughout 2025, demonstrating its disciplined approach to capital allocation and shareholder returns.
Clarivate retires $100M 2026 notes, spends $225M on buybacks
Clarivate (NYSE: CLVT) announced that its subsidiary fully redeemed the remaining $100 million of its 4.50% senior secured notes due 2026 on January 30, 2026. This action, funded with cash on hand, is part of Clarivate's capital allocation strategy, which also included repurchasing approximately 56 million ordinary shares for $225 million in 2025. The company aims to simplify its capital structure, reduce debt, and enhance financial flexibility through these strategic moves.
Clarivate Terminates Indenture With Wilmington Trust
Clarivate PLC has terminated its Indenture with Wilmington Trust, which governed its 4.50% Senior Secured Notes due 2026. The termination occurred after Clarivate fully redeemed these notes on January 30, 2026, by depositing sufficient funds to cover principal and accrued interest. This action simplifies Clarivate's capital structure and removes associated secured debt obligations.
Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities
Clarivate Plc announced the full redemption of the remaining $100 million of its 4.50% senior secured notes due 2026, which was funded by cash on hand and completed on January 30, 2026. This action is part of the company's strategy to simplify its capital structure and reduce debt. Additionally, Clarivate repurchased approximately 21 million ordinary shares for $75 million in Q4 2025, bringing the total repurchases for 2025 to 56 million shares for $225 million, demonstrating a disciplined approach to returning capital to shareholders.
Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities
Clarivate Plc announced the full redemption of its remaining $100 million aggregate principal amount of 4.50% senior secured notes due 2026, which was completed on January 30, 2026. This action, funded with cash on hand, aligns with the company's strategy to simplify its capital structure, reduce debt, and enhance financial flexibility. Additionally, Clarivate repurchased approximately 21 million ordinary shares for $75 million in Q4 2025, bringing the total repurchases for 2025 to 56 million shares for $225 million, demonstrating its commitment to returning capital to shareholders.
Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026
Clarivate Plc announced it will report its financial results for the fourth quarter and full year 2025 before the market opens on Tuesday, February 24, 2026. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results. Financial information will be available on the Clarivate investor website.
Clarivate recognized in WTR 1000 for trademark excellence
Clarivate has been recognized in the WTR 1000 for the third consecutive year, receiving "highly recommended" status across three categories: renewals and recordals, searching and watching, and trademark management. This recognition highlights Clarivate's expertise, dedication, and innovative solutions that help organizations protect and strengthen their brands. The company's commitment to delivering accurate, efficient, and reliable trademark services is underscored by this industry acknowledgment.
Clarivate (CLVT) reveals new AI academic assistant, to launch in Q3 2026
Clarivate Plc (CLVT) has announced the development of an AI academic assistant, designed to enhance the research process for academics and students. This new tool, which leverages Clarivate's extensive intellectual property and data, is anticipated to launch in the third quarter of 2026. The assistant aims to provide sophisticated support for discovery, writing, and submission workflows, thereby improving research efficiency.
Clarivate stock hits 52-week low at $2.78
Clarivate PLC's stock recently hit a new 52-week low of $2.78, marking a 49.46% decline over the past year. Despite this, InvestingPro data suggests the stock is undervalued with a low Price/Book multiple of 0.38 and an impressive 18% free cash flow yield. The company's Q3 earnings surpassed expectations, leading to a raised 2025 revenue outlook, though analysts like Goldman Sachs and Morgan Stanley have downgraded the stock due to concerns about its Value Creation Plan and growth projections.
Clarivate (CLVT) Reveals New AI Academic Assistant, To Launch in Q3 2026
Clarivate Plc (NYSE: CLVT) has announced Clarivate Nexus, an AI-powered academic assistant designed to integrate library content and services with AI tools used by students and researchers. This new tool, part of Clarivate's expanding academic AI services, will be released for early access in Q3 2026, initially as a browser extension before direct integration into campus systems. The company also recently signed a multi-year agreement with Iran’s Ministry of Higher Education and Scientific Research.
Clarivate (CLVT) Reveals New AI Academic Assistant, To Launch in Q3 2026
Clarivate Plc (NYSE: CLVT) has announced Clarivate Nexus, an upcoming AI-powered academic assistant designed to integrate library content and services with AI tools used by students and researchers. This new service, part of Clarivate's expanding academic AI offerings, will first be available as a browser extension in Q3 2026, with future plans for direct integration into campus systems. The company also recently entered a multi-year agreement with Iran’s Ministry of Higher Education and Scientific Research for strategic guidance and data services.
Evaluating the societal impact of research: Insights from the global community
A global survey of over 2,500 research office staff and researchers reveals how institutions prioritize and measure the societal impact of research. Key findings include regional differences in evaluation drivers, the continued dominance of traditional academic publications, and the identification of policy citations and media mentions as important proxy measures. The article highlights the challenge of measuring direct societal impact and the need for flexible, context-aware assessment solutions.
Clarivate stock hits 52-week low at $2.78 By Investing.com
Clarivate PLC's stock recently hit a new 52-week low of $2.78, marking a significant 49.46% decline over the past year. Despite this, InvestingPro data suggests the stock is undervalued, trading at a low Price/Book multiple of 0.38 with an 18% free cash flow yield. The company's recent Q3 earnings surpassed expectations, leading to a raised 2025 revenue outlook, though it also faced downgrades from Goldman Sachs and Morgan Stanley due to concerns over its Value Creation Plan and growth projections.
Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026
Clarivate Plc (NYSE: CLVT) announced it will report its financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026, before market open. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results. Financial information and webcast access details will be available on the Clarivate investor website.
Clarivate stock hits 52-week low at $2.78
Clarivate PLC's stock recently hit a new 52-week low of $2.78, marking a significant 49.46% decline over the past year due to challenging market conditions. Despite this, InvestingPro data indicates the stock trades at a low Price/Book multiple of 0.38 with an impressive free cash flow yield of 18%, suggesting it might be undervalued according to analyst targets. While the company reported better-than-expected Q3 earnings and raised its 2025 revenue outlook, it faced downgrades from Goldman Sachs and Morgan Stanley due to concerns about its Value Creation Plan timeline and growth projections.
Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026
Clarivate Plc (NYSE: CLVT) announced it will report its financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026, before the market opens. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to review these results. Further financial information and access to the webcast will be available on the Clarivate investor relations website.
Silicon Motion Named a Clarivate Top 100 Global Innovator 2026
Silicon Motion Technology Corporation has been recognized as a Clarivate Top 100 Global Innovator for 2026, marking its inaugural inclusion on the prestigious list. This award acknowledges Silicon Motion's consistent delivery of high-impact inventions, particularly in NAND flash controller innovation, and its strong intellectual property strategy. The company is committed to advancing AI storage technologies, aiming for higher performance and efficiency to meet evolving AI workload demands.
Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026
Clarivate Plc announced it will report its financial results for the fourth quarter and full year 2025 before the market opens on Tuesday, February 24, 2026. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results, with financial information available on its investor website. A replay of the webcast will also be accessible for one year.
Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026
Clarivate Plc (NYSE: CLVT) announced that it will report its financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026, before market open. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results, with financial information available on its investor relations website. Clarivate is a global provider of transformative intelligence across academia, intellectual property, and life sciences.
UPC PI outcomes: Grant rates & speed by Division
This article analyzes preliminary injunction (PI) outcomes at the Unified Patent Court (UPC) over its first two years, focusing on grant rates and decision speed across different divisions. It reveals that while overall PI grant rates have become more patentee-friendly, significant differences exist between divisions, with Munich showing the highest grant rate and The Hague offering the fastest resolutions. The findings underscore the importance of strategic forum selection for patentees based on their priorities for speed versus success likelihood.
Epson Ranks 6th In Clarivate Top 100 Global Innovators List For 2026
Epson has been recognized as a top global innovator, ranking 6th in Clarivate's 2026 list of Top 100 Global Innovators. This marks the 13th time Epson has appeared on the list, demonstrating its consistent commitment to developing new technologies and intellectual property. The company views its IP assets as crucial for long-term growth and competitive advantage, driving continuous investment in R&D and product differentiation.
Epson Ranks Clarivate Top 100 Global Innovators 2026
Epson has been recognized as a Clarivate Top 100 Global Innovator for the 13th time since 2012, maintaining its 6th position from the previous year. Clarivate evaluates companies based on patent data, innovativeness, and global reach. Epson emphasizes the importance of intellectual property in supporting its brand value and continuous investment in research and development.
